The Foundation for the National Institutes of Health (FNIH) works with partners like you to advance breakthrough biomedical discoveries and improve the quality of people’s lives. As a 501(c)(3) charity chartered by Congress, the FNIH depends on private philanthropy to support vital scientific research, education and training, awards and patient care activities at the National Institutes of Health (NIH), the world’s largest biomedical research agency. The FNIH’s team of scientists, program managers and fundraisers works hand-in-hand with you each day to shape the future of human health.

Read more: fnih.org/AnnualReport
Dear Friends,

We begin by saying thank you! Thank you for your time, forward-thinking ideas, generous support and dedication to biomedical research.

You equip the FNIH with the essential resources needed to advance transformative biomedical research in support of the mission of the NIH and to have global impact. In 2017, you helped us reach the amazing milestone of raising more than $1 billion since our inception. These private-sector dollars are critical for breakthrough discoveries that improve the quality of people’s lives.

Your generous support allows us to convene large networks of scientific leaders to seek new knowledge and catalyze research collaborations to improve health, lengthen life and reduce illness and disability. These alliances foster innovation and channel resources for maximum impact — achieving results far greater than what can be accomplished by any single organization.

In this 2017 Annual Report, we are delighted to highlight a few examples of the support and commitment of some of our partners and donors. In these vignettes, you will learn about projects that are solving some of the major unanswered questions of biomedical research, training the next generation of clinician-scientists, honoring outstanding scientific achievements and helping NIH patients and their families.

The work that you have supported has allowed the FNIH to be honored and recognized internationally last year. In 2017, the FNIH was named the “#1 Charitable Biomedical Research Organization” by Charity Navigator and earned a Gold Stevie Award for “Organization of the Year.”

So, once again, the FNIH Board of Directors and staff want to recognize the contributions of all of those individuals and organizations that have made our work possible. Thank you for your trust and support and for helping us shape the future of human health. We look forward to working closely with you in the years to come.

Maria C. Freire, Ph.D.
PRESIDENT AND EXECUTIVE DIRECTOR

Steven M. Paul, M.D.
CHAIRMAN

Maria C. Freire, Ph.D.
PRESIDENT AND EXECUTIVE DIRECTOR

FNIH 2017 Annual Report
Individuals

Individuals have the power to address some of the most vexing health challenges of today. Supporting the FNIH with unrestricted donations allows the FNIH to leverage and strategically deploy funds where they are most needed. Further, donors may wish to support specific areas of interest — from research in certain diseases to patient care.

Andrew Lee

At age 22, Andrew Lee is driven. Following his HLRCC diagnosis, Andrew established the not-for-profit Driven to Cure, Inc. He now travels the country attending car events to raise visibility and funding for rare kidney cancers.

In December 2017, Andrew presented a $100,000 check to Maria C. Freire, Ph.D., FNIH President and Executive Director. This donation, in addition to a $200,000 gift made in 2016, will further cutting-edge research on rare kidney cancer conducted by the National Cancer Institute (NCI) at the NIH Clinical Center.

“When I was diagnosed with stage 4 HLRCC rare kidney cancer at age 19, I was told I had six to 12 months to live. I was immediately accepted to the HLRCC trial at the NIH in June of 2015. I know and understand there is currently no known cure for HLRCC, but without the research happening today, we would not help those who will be in need tomorrow.”

—Andrew Lee
President of Driven to Cure, Inc.
The cultural and philanthropic contributions of Buffy Cafritz are ever present around the country, especially just 10 miles north of Washington, D.C. on the NIH campus in Bethesda, MD.

Mrs. Cafritz’s unwavering commitment to the FNIH has supported students, patients and researchers at the NIH for nearly two decades. She and her husband have helped students interested in Parkinson’s disease train with renowned scientists by funding the NIH Medical Research Scholars Program, thus supporting a new generation of clinician-scientists. Mrs. Cafritz also sponsors a room at the Edmond J. Safra Family Lodge just footsteps away from the NIH Clinical Center, so that patients and their families can stay together during treatment.

Mrs. Cafritz and the Buffy and William Cafritz Family Foundation’s commitment to biomedicine extends to research in the laboratory. In 2017, their support created a five-year competitive grant program at the NCI to develop highly innovative approaches and technologies for kidney cancer. Through her dedication to this significant work, Mrs. Cafritz’s presence in biomedical research will be felt for generations to come.

It has been a pleasure to support the FNIH throughout the years to further pioneering biomedical research, crucial student training and activities that help heroic patients participating in clinical trials. The nimble, yet powerful FNIH team, is making important medical discoveries possible. I am proud to be a part of their work, which will benefit our world far into the future.”

— Buffy Cafritz
HONORARY TRUSTEE, THE JOHN F. KENNEDY CENTER FOR THE PERFORMING ARTS, AND FNIH BOARD MEMBER
Ms. Carol-Ann Harris

Ms. Carol-Ann Harris of Fort Lee, NJ, advances muscular dystrophy research through the CarMollNat Endowment at the FNIH.

“Muscular dystrophy has affected my family for at least seven generations. I felt it was my calling to honor my loved ones by investing in the FNIH so that important research can propel this field forward and help future patients and their families in the years to come.”

– Ms. Carol-Ann Harris

Barbara Lazio, M.D., and Mr. Matthew Scher

Barbara Lazio, M.D., and Mr. Matthew Scher of Olympia, WA further cancer research by donating annually to the FNIH in honor of their mothers, who passed away from the disease.

“After losing some of our closest family members and friends to cancer, we felt we needed to support ongoing research to benefit future cancer patients. There are many charities soliciting funds for cancer research, but we felt by investing in the FNIH, our money would be applied to the most highly vetted and innovative research. We really just want to keep the fire burning, support the innovators, see these baby steps develop into something that can eventually impact a person’s life.”

– Barbara Lazio, M.D.

A physical therapist helps a boy with muscular dystrophy exercise.
Mrs. Lily Safra

As lead benefactor of the Edmond J. Safra Family Lodge (Family Lodge), Mrs. Lily Safra has made housing available for about 130,000 adult patients of the NIH Clinical Center and their loved ones since 2005. These brave patients travel with their families from around the world to participate in vital research at the NIH Clinical Center, which is known for its history of medical breakthroughs, including the development of chemotherapy for cancer and the first AIDS treatment.

Located within walking distance of the NIH Clinical Center, this English manor-style residence features 34 spacious guest rooms. Its elegant kitchen, library, fitness and business centers, and gardens, alongside its dedicated onsite team, offer families a home-like place of respite during their time of need. By caring for these courageous families, Mrs. Safra is ensuring crucial biomedical research rapidly progresses to improve the health of current patients and those in the years ahead. Learn more about the Family Lodge at fnih.org/FamilyLodge.

“I know from personal experience how when one person becomes ill, a whole family is affected. By providing a warm and comfortable environment for patients’ families at the Edmond J. Safra Family Lodge, I hope that more people will be able to seek treatment and participate in vital clinical research efforts at the NIH Clinical Center.”

– Mrs. Lily Safra

CHAIRWOMAN OF THE EDMOND J. SAFRA PHILANTHROPIC FOUNDATION AND FNIH BOARD MEMBER
Not-for-Profits and Foundations

Not-for-profit and foundation partners have helped the FNIH orchestrate programs to develop preventive medicines, diagnostic tools and new therapies and to train the next generation of clinician-scientists. Often working closely with government and industry partners, these organizations keep patients top-of-mind — bringing their critical perspective to FNIH programs.

**McKnight Brain Research Foundation**

The McKnight Brain Research Foundation (MBRF)'s decade-long partnership with the FNIH has expanded understanding of how people think as they age, through co-sponsorship of the Research Partnership in Cognitive Aging and three Cognitive Aging Summits with the National Institute on Aging (NIA).

“This partnership has facilitated exploration of new avenues of potential research within the scientific community, which could lead to the development of pharmacological and behavioral interventions, and ultimately improved outcomes in cognitive health. A very important outcome has also been raising the level of awareness within the scientific community and among the public about the importance of this research and its tremendous value to society in preserving and maintaining cognitive health.”

— J. Lee Dockery, M.D.
CHAIR, BOARD OF TRUSTEES, MBRF

**Amgen Foundation and Doris Duke Charitable Foundation**

The FNIH supports training programs at the NIH that enable students interested in biomedicine to work closely with some of the world’s leading researchers. These programs are made possible with partners including the Amgen Foundation and the Doris Duke Charitable Foundation.

“By partnering with the FNIH — in addition to institutions such as Harvard, MIT and Cambridge — we are opening the door to ground-breaking research opportunities in biomedical research that continue to advance human health in untold ways. If your mission is to inspire and train the next generation in biomedical research — or to advance scientific breakthroughs into human health — the FNIH needs to be on your short list as an organization worth partnering with.”

— Scott Heimlich, Ed.D.
VICE PRESIDENT, AMGEN FOUNDATION

“Our partnership with the FNIH supports the Medical Research Scholars Program, which gives medical students a hands-on clinical research experience under the guidance of successful scientists. We are proud to support this program as an avenue for igniting in students a passion for research that can translate into a productive, lifelong career as a physician scientist.”

— Betsy Myers, Ph.D.
PROGRAM DIRECTOR FOR MEDICAL RESEARCH, DORIS DUKE CHARITABLE FOUNDATION
Addressing some of the world’s most pressing health challenges, including tuberculosis and malaria, requires the proficiency of indomitable scientists backed by excellent project management and stable financial support. For more than a decade, the Bill & Melinda Gates Foundation (Gates Foundation) has worked with the FNIH to develop strong ecosystems that underpin scientific discovery and foster creation of emerging technologies to provide novel solutions to fight disease.

In 2017, among other key accomplishments, this work resulted in the publication of the Guiding Principles for Sponsors and Supporters of Gene Drive Research in *Science*. Considered an emerging technology, gene drive can be used to promote the preferential inheritance of a beneficial trait, thereby increasing its prevalence in a population. The developers and signatories of these guiding principles are committing to support research of the highest scientific and ethical quality, inspire a transparent approach and back relevant biosafety measures and best practices. Learn more about this work at fnih.org/GeneDrivePrinciples.

The Gates Foundation’s Steven Buchsbaum, Ph.D., reflected on the foundation’s longstanding partnership with the FNIH:

“The FNIH was, in the very early days of the Gates Foundation, a key partner that we chose to first begin investing in basic science for global health. That started with the original Grand Challenges in Global Health, which the FNIH was our key partner in formulating and executing.

Having had the opportunity to see projects evolve and mature over more than a decade, there are a number of them that were called for, selected, invested and nurtured either by the FNIH themselves or jointly with us that are incredibly promising in the sense that they are transformational new tools for global health. One example is the Eliminate Dengue project (now called the World Mosquito Program) and another is the Target Malaria initiative. But perhaps more than that, and harder to measure and directly attribute, is really just the change in the scientific community in the sense of the excitement, attention paid and amount of research that is done on health conditions that affect the majority of the population in the world, but particularly those that are poor and underserved.”

“The FNIH was chosen both because of its unique and integral relationship with the NIH and its uniquely qualified staff.”

– Steven Buchsbaum Ph.D.
DEPUTY DIRECTOR, DISCOVERY & TRANSLATIONAL SCIENCES, GATES FOUNDATION
Government agencies are the bedrock of FNIH partnerships. For two decades, the FNIH has worked with federal agencies to build powerful initiatives with the private sector that have changed the way researchers, regulators, doctors and patients understand and treat disease.

Congress chartered the FNIH to raise private funds to support the world’s largest biomedical research agency, the NIH. The FNIH leverages the know-how and resources of the private sector to work with the NIH to tackle complex biomedical challenges. In 2017, the FNIH, NIH, U.S. Food and Drug Administration (FDA) and 12 biopharmaceutical companies launched the historic $220 million Partnership for Accelerating Cancer Therapies (PACT) to better understand how to harness the immune system to attack cancer. Learn more at fnih.org/PACT.

“The FNIH makes it possible for the NIH, as a government facility, to work with the private sector to answer some of the world’s most pressing health questions. Through innovative research partnerships, the NIH and FNIH are able to fuel the biomedical discoveries needed for better diagnosis, prevention, treatment and cure of disease. Working with the FNIH is vital to the research enterprise.”

– Francis Collins, M.D., Ph.D.
DIRECTOR, NIH

A pseudo-colored scanning electron micrograph of an oral squamous cancer cell (white) being attacked by two cytotoxic T cells (red), part of a natural immune response.
Credit: National Cancer Institute / Duncan Comprehensive Cancer Center at Baylor College of Medicine
In October 2017, FNIH Chairman Dr. Steven M. Paul and President and Executive Director Dr. Maria C. Freire presented NIA Director Dr. Richard Hodes with a Charles A. Sanders, M.D., Partnership Award.

“The FNIH offers a great venue to bring together the NIH, FDA, academia and the pharmaceutical industry to conduct robust translational research that will enable more informative and better targeted medical product development.”

– Janet Woodcock, M.D.

DIRECTOR, CENTER FOR DRUG EVALUATION AND RESEARCH, FDA, AND EXECUTIVE COMMITTEE MEMBER OF THE FNIH BIOMARKERS CONSORTIUM

National Institute on Aging

The NIA, under the inspired leadership of Director Richard Hodes, M.D., has been one of the FNIH’s most significant and longstanding partners. Over the past decade, the NIA and the FNIH have developed new collaboration models, governance structures and data-sharing policies for such groundbreaking programs as the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the Accelerating Medicines Partnership (AMP). Dr. Hodes reflected on this partnership with the FNIH:

“The benefit of collaborations, scientific meetings and other support provided to NIH through the Foundation is not limited to the institute or institutes whose work is being facilitated. These efforts galvanize all partners in moving toward shared goals. We have seen this in several areas, most recently in the emergence of the new discipline of geroscience, where Foundation efforts have facilitated conferences that have helped develop new synergy between researchers in the basic biology of aging and scientists focused on specific diseases associated with advanced age, such as cancer and heart disease. This new approach has enhanced the recognition of aging as the critical risk factor underlying disease development in many cases and has fostered new connections among public and private sector scientists seeking to reduce disease risk and improve health for older people.”

U.S. Food and Drug Administration

The FDA, the U.S. regulatory agency for biomedical technologies, is a primary partner actively engaged in FNIH public-private consortia that formulate and lead cutting-edge research programs.

The FNIH Biomarkers Consortium manages many of these programs, which often have regulatory implications. The mission of the Biomarkers Consortium is to discover, develop and seek regulatory approval of biological markers (biomarkers) to support development of new diagnostic tools and drugs within four key areas: cancer, inflammation and immunity, metabolic disorders and neuroscience. In 2017, the Biomarkers Consortium reached several milestones, including the publication of a framework to guide biomarker qualification in Science Translational Medicine, as well as submitting recommendations to the FDA to guide drug development for serious hospital-acquired bacterial infections. Learn more about Biomarkers Consortium projects at fnih.org/BiomarkersConsortium.
Industry

Industry partners work with the FNIH to build powerful scientific collaborations that fuel biomedical discovery. By bringing world-class scientists, critical datasets, the latest technology and financial resources to these partnerships, industry helps the FNIH facilitate the exchange of ideas in a pre- or non-competitive environment that would not be possible otherwise.

“I believe that every dollar donated to FNIH will ‘punch above its weight’ in the fight against disease and will open the doors for value-added partnerships to speed the flow of new cures.”

— Freda C. Lewis-Hall, M.D., DFAPA
EXECUTIVE VICE PRESIDENT AND CHIEF MEDICAL OFFICER, PFIZER, AND FNIH BOARD MEMBER

Pfizer

Pfizer's sustained commitment to the FNIH spanning two decades has bolstered a suite of biomedical initiatives on topics from genetics to lung cancer, laying the groundwork for important discoveries.

The company's scientific leadership and financial support to the FNIH have expanded understanding of the genetic causes of common diseases, enabled pediatric testing programs for drugs and increased knowledge of Alzheimer's and lung cancer, to name a few. It also furthered the careers of research-oriented medical and dental students by sponsoring training at the NIH.

Additionally, Pfizer leaders, including Dr. Freda C. Lewis-Hall, have brought their vision and expertise to the FNIH Board of Directors. “The world is chock-full of promising scientific leads and information that is valuable in the service of patients, and the FNIH is a key conduit in the flow of these ideas,” said Dr. Lewis-Hall. “It’s hard to believe that the FNIH has been operating for just over 20 years, as its become such an important facilitator of the public-private partnerships that ultimately expand the universe of biomedical science, especially the science that can be translated into new therapies and the science that provides a rocket-boost to other medical research endeavors.”
Lilly

Since 2000, Lilly and the FNIH have advanced critical research to increase scientific understanding across multiple diseases, including osteoporosis, lung cancer and Alzheimer’s disease, through 44 projects.

In particular, Lilly played an essential role in the establishment of the Alzheimer’s Disease Neuroimaging Initiative (ADNI), becoming the first company to join the partnership 13 years ago and championing support from other industry representatives. “ADNI has increased our understanding of Alzheimer’s disease (AD) by identifying and validating biomarkers, including specific imaging for tau and amyloid as hallmarks of this disease that indicate the onset and progression of AD,” explained Lilly’s Jan Lundberg, Ph.D. “ADNI’s work helps biopharmaceutical companies like Lilly improve clinical trial design and test new medicines.” Read about ADNI at fnih.org/ADNI3.

Lilly also supports projects within the FNIH Biomarkers Consortium and is a significant proponent of the Accelerating Medicines Partnership (AMP), particularly the AMP-AD and the AMP Type 2 Diabetes projects. “Data from AMP and other FNIH partnerships are guiding our evolving strategy for AD and diabetes drug discovery and development,” said Dr. Lundberg. “Ultimately, that will benefit millions of patients including understanding disease sub-classification and patient stratification signature.” Learn more about AMP at fnih.org/AMP.

Dr. Lundberg continued, “It is essential to encourage the exchange and robust scientific discussion of new ideas. To this end, I would say the number one benefit to Lilly from our investment in FNIH is the foundation’s ability to accelerate biomedical research by creating public-private partnerships where scientists interact and learn from each other across different sectors of the biomedical healthcare system, including regulatory authorities.”

“Public-private partnerships involving the biopharmaceutical industry, NIH and academia have advanced key areas of human disease understanding and the potential for diagnostics and therapies by unifying resources and capabilities and making findings public.”

— Jan Lundberg, Ph.D.
EXECUTIVE VICE PRESIDENT, SCIENCE AND TECHNOLOGY AND PRESIDENT, LILLY RESEARCH LABORATORIES

In October 2017, Lilly Executive Vice President Dr. Jan Lundberg accepted a Charles A. Sanders, M.D., Partnership Award on the company’s behalf.
and thanks each of our valued partners, whose generosity provides the critical resources needed to accelerate scientific discoveries to diagnose, treat and cure the world’s most devastating diseases. Unrestricted gifts allow the flexibility to use donations where they are urgently needed, while restricted gifts serve a specific area of research. Other donors choose to partner and establish funds and endowments to pay tribute to loved ones.
To learn more about ways to give, please select from the following links:

**Partners for Innovation, Discovery and Health Society:**
Learn more at fnih.org/PartnersSociety.

**Legacy Society:**
For questions regarding bequests or estate planning visit fnih.org/PlannedGiving and join others who include the FNIH in their estate plans at fnih.org/LegacySociety.

**Tribute and Memorial Giving:**
Learn more about gifts to honor someone special at fnih.org/TributeGiving.

**Funds and Endowments:**
Contribute to or establish a fund or endowment that advances research in a particular area of interest by searching FNIH programs at fnih.org/Programs.

**Research Programs:**
Find a specific research program to donate to at fnih.org/ResearchPrograms.

For a complete list of donors, funds and endowments, visit fnih.org/AnnualReport. Please call 301.402.4976 or email advancement@fnih.org with questions.
## Our 2017 Donors

*Our 2017 Donors*

<table>
<thead>
<tr>
<th>Key</th>
<th>Gifts in Kind</th>
<th>Member of the Partners for Innovation, Discovery and Health Society</th>
<th>New Members of the Legacy Society</th>
</tr>
</thead>
<tbody>
<tr>
<td>$5,000,000+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amgen, Inc. 15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AstraZeneca Pharmaceuticals, LP 16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bristol-Myers Squibb Company 18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Johnson &amp; Johnson 17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novartis Pharmaceuticals Corporation 18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer Inc 20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$2,500,000– $4,999,999</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anonymous ∞</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AbbVie Inc. 9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bill &amp; Melinda Gates Foundation 16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GlaxoSmithKline 19</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eli Lilly and Company 18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Merck Sharp &amp; Dohme Corp. 20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pernod Ricard 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$1,000,000– $2,499,999</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anheuser-Busch InBev 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biogen 7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carlsberg Breweries A/S 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Celgene Corporation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diageo Plc 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMD Serono, Inc. 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Michael J. Fox Foundation for Parkinson's Research</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gilead Sciences, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HEINEKEN 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McKnight Brain Research Foundation 12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Institutes of Health 8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pernod Ricard 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$750,000– $999,999</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthritis Foundation 8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bayer HealthCare Pharmaceuticals Inc. 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congress of Neurological Surgeons 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crescendo Bioscience, Inc. ∞</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Driven To Cure, Inc. 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation for AIDS Research</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genentech, Inc. 11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>George Vradenburg Co-Founder USAgainst Alzheimer’s ∞</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$500,000– $999,999</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buffy Cafritz 14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Research Associates, LLC, an affiliate of the Simons Foundation 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ann Lurie 6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wyeth Nutrition 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$250,000– $499,999</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estate of Jonathan D. Gest ∞</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmaceutical Research and Manufacturers of America 13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals, Inc. 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TissueGene, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$100,000– $249,999</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthritis Foundation 8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bayer HealthCare Pharmaceuticals Inc. 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congress of Neurological Surgeons 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crescendo Bioscience, Inc. ∞</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Driven To Cure, Inc. 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation for AIDS Research</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genentech, Inc. 11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>George Vradenburg Co-Founder USAgainst Alzheimer’s ∞</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$50,000– $99,999</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alector</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alzheimer’s Association ∞ 13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>American Association for Dental Research 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Critical Path Institute &amp; the Predictive Safety Testing Consortium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Denali Therapeutics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GE Healthcare 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mr. and Mrs. Paul M. Montrone 20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxford BioDynamics Plc</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steven and Jann Paul 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROCHE 10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saladax Biomedical, Inc</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fred A. and Donna Seigel ∞</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$25,000– $49,999</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adaptive Biotechnologies 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Geoffrey Beene Foundation Alzheimer’s Initiative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BioClinica, Inc. 10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elsevier, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GHR Foundation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liz and Eric Lefkofsky</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mr. and Mrs. Joel S. Marcus ∞ 7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mayo Clinic 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Dairy Council 7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ortho Clinical Diagnostics 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bill and Giuliana Rancic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatology Research Foundation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Andrew Steinhaus 2</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Key: Number of Years of Consecutive Giving, Gifts in Kind, Member of the Partners for Innovation, Discovery and Health Society, New Members of the Legacy Society*
$10,000–$24,999

23andMe, Inc.
Accelerate Cure/Treatments for Alzheimer's Disease (ACT-AD)
American Society for Bone and Mineral Research
Araclon Biotech
Bio-Rad Laboratories, Inc.
Citigroup Inc.
Cleary Gottlieb Steen & Hamilton LLP
CogState Ltd
Davis Polk & Wardell LLP
DiamirR, LLC
James H. and Christina W. Donovan
EUROIMMUN AG
Andrew and Michelle Feinberg
Estate of Linda Founds
Estate of Jack Gramlich
Illumina, Inc.
Dr. and Mrs. Thomas R. Insel
James Jones
In memory of Brenda S. Jones
MagQu Co., Ltd.
March of Dimes Birth Defects Foundation
Steve and Sherry Mayer
Medtronic, Inc.
Martin J. Murphy, Ph.D. and Ann Murphy, Ph.D.
Bob and Sally Newcomb
Northwestern Medicine
Olink Proteomics
Paul, Weiss, Rifkind, Wharton & Garrison LLP
PeopleBio, Inc.
Piramal Imaging, GmbH
Curt and Linda Rodin
Dame Jillian Sackler
Jane M. Sayer, Ph.D.
Gerald R. Sigal and Ellen V. Sigal, Ph.D.
Solomon H. Snyder, M.D.
The Society for Immunotherapy of Cancer
Nina K. Solarz
SomaLogic, Inc.
Russell W. Steenberg and Patricia Colbert
Clara J Szekely Foundation Inc.
UCB, Inc.

$5,000–$9,999

Anonymous
AARP
Jeffrey Abrams, M.D.
Alzheimer's Drug Discovery Foundation
American Association of Colleges of Nursing
American Diabetes Association
AFTD (Association for Frontotemporal Degeneration)
Avanir Pharmaceuticals
Paula L. and William C. Bradley
Laura Catena, M.D.
Ralph H. and Karen K. Craft
The Geaton & JoAnn DeCesaris Family Foundation, Inc.
In honor of Betty DeCesaris
Doris Duke Charitable Foundation
Susan E. Finley
Fisher Foundation
Frederick National Laboratory for Cancer Research
Ernesto I. Freire, Ph.D. and Maria C. Freire, Ph.D.
Theodore N. Giovannis, M.B.A.
Carol-Ann Harris
Home Instead Senior Care
Invitae
Keith R. Leonard, Jr.
Lawrence Mayer
William Morley and Caroline Trahan
The Multiple Myeloma Research Foundation
Jinnah Phillips, M.D.
Radiological Society of North America
Sunny Raspet
Robert E. Roberts, Ph.D.
In memory of Anita Roberts
Charles A. Sanders, M.D. and Ann E. Sanders
Joshua Sasouness
In honor of Rod Hubbard
Matthew Scher and Barbara Lazio
In memory of Barbara L. Lazio, Carol Scher and Jane Scher
Sullivan & Cromwell LLP
Ullmann Family Foundation
WellMed Charitable Foundation
The Richard H. Yearick Foundation
Elias A. Zerhouni, M.D. and Nadia Zerhouni, M.D.
Steve and Chris Wilsey

$2,500–$4,999

Marc and Anita Abramowitz
The Beckman Research Institute of City of Hope, Department of Population Sciences, Division of Nursing Research and Education
Ronald and Barbara Berke
In memory of Jenny Berke
Facebook
Chris and Laura C. Hazzard
In memory of Richard Curtin
W. Seymour Holt, M.D. and Rheta Holt
Julie Bell Lindsay
In memory of T. Douglas Lindsay
Catherine Master
In honor of Larry Doll, Ann Halverson, Mo Henderson, Betty Parker and Steve Seifert
James Muldoon
Oncology Nursing Society
PTA Jankowski Charitable Fund
Alan S. Rabson, M.D.
Linda P. Reed
John and Katrina Rogers
In memory of Brenda S. Jones
Steven L. and Karin Siegel
The Honor Society of Nursing, Sigma Theta Tau International (STTI)
SunTrust Banks, Inc.
Samuel O. Thier, M.D. and Paula Thier
Sara Lou Whildin
Steve and Chris Wilsey
Anonymous (3) 
Kimberly Allen 
Apple Inc. 
John and Sandra Atkins 
Dr. Nadarajah Balasubramanian 
Robert Balthaser and Ricardo C. Araneda, Ph.D. 
Frederick C. and Rebecca B. Becker 
Joe Bergera and Alice S. Cho 
Zachary T. Bloomgarden, Ph.D. and Kathy F. Bloomgarden, Ph.D. 
Christopher J. Boyd and Jamie N. Cooper 
Brian V. Breheny and Pedro Lay 
In memory of T. Douglas Lindsay 
Marc and Debbie Breslasky 
Ambassador and Mrs. Dwight L. Bush, Sr. 
Calibre Systems Inc 
Calico Labs 
Charles Cerf and Cynthia E. Dunbar, M.D. 
Ken Chang 
Clark Family Gifting Trust 
Craig and Susan Clendening 
Daniel Cunningham and Mary Hennessey 
Max Delgadillo 
Deloitte Consulting LLP 
Alicia Emerson 
In memory of Scott Emerson 
FS Networks 
Faith United Methodist Church 
Friedman Family Gift Fund 
In memory of Ruth Friedman 
James and Karen Gavic 
Stanley and Eve Geller 
Eileen Grams 
Margaret Grieve 
In honor of Nina K. Solarz and in memory of Stephen J. Solarz 
Rizwan H. Habeeb, M.D. 
Paul Heider 
Dr. and Mrs. Paul L. Herrling 
IQ Solutions 
Jean Janklow Estrin 
Laura Jansen 
Arthur H. and Jean B. Jerbert 
Alex Johnson, Ph.D. 
Bernard H. and Georgina E. Kaufman 
Kevin and Teresa Klock 
In memory of Fred and Helen Balding 
William Knowlton 
In memory of Linda Knowlton 
Jeremy Krasner 
Arnold Lakind 
Sherry Lansing and William Friedkin 
Howard H. and Jacqueline K. Levine 
In memory of Stephen J. Solarz 
Jonathan D. Levine 
John Madden, Jr. 
Margaret and James Malaro 
Marriott International 
Patrick and Barbara McGarey 
Raymond Michael 
Nabil A. Moufarrej, M.D. 
Navitor Pharmaceuticals 
Donna Nichols 
In honor of Mattison C. Painter 
Omega World Travel Inc. 
Matthew W. O'Neill and Erica Joyce Lam 
In memory of Dean R. O'Neill 
Susanne N. O'Neill 
In memory of Dean R. O'Neill 
Matt and Robyn Nichols Painter 
Paragon Pharmaceuticals 
Carl L. Quinn 
Cheryl M. Rakestraw 
Jane Robinson 
Gregory and Sherry Roper 
Robert and Marjorie Rosenberg 
Stanley O. Roth 
Saks Fifth Avenue 
Lenore R. Salzman 
In memory of Norman P. Salzman 
Richard I. and Anastasia Smith 
Sobi, Inc. 
Dr. Ann K. Syrdal 
Andrew Traficanto 
The Drs. Tremoulet 
Jon and Kristin Vaver 
Mr. Mehdi Nafissi and Dr. Ann F. Welton 
David Wholley 
Stewart K. Wilson 
In memory of Blaise Ribet, Alan Wilson, Beulah Wilson and Christina Wilson 
Wolzinger Family Foundation 
Richard G. Wyatt, M.D. and Linda S. Wyatt, Ph.D. 
Lucas and Katrina Yun-Nikolac 
Daniel Zhao 
In memory of Michelle
Anh Do
∞
In honor of Khanh Tu and H. Tran
Ronald Early 3
∞
Michael Erickson 7
James M. Felser, M.D. 8
In memory of Stephen E. Straus
Nicholas M. and Jacqueline E. Ferriter 4
Jeffrey and Marilyn Finn 2
∞
Keith Gendler 2
∞
Gene and Esther Gorman 3
Randall and Holly Griffin
In memory of Brian Griffin
Joe Grossman 7
∞
Ken and Yvette Guidry 1
Joyce B. Harp, M.D. 8
William Harris, M.D. 8
Kay A. Hart 2
Thomas H. and Rita R. Hassall 2
Healthy Directions LLC
Kelley Hearne
In memory of T. Douglas Lindsay
Eric Hirschhorn and Leah Wortham 7
In memory of Stephen J. Solarz
Girard and Pauline Ann Histed 7
In honor of Pauline Ann Histed
The Martha B. and Michael S. Horne Charitable Fund 4
Susan C. Horowitz 6
∞
In memory of Arthur G. Horowitz
Harold Huston 3
∞
In honor of Laura Huston
Terrance J. Jach and Paula J. Warrick 6
∞
Stephanie L. James, Ph.D. 7
∞
James F. and Gudrun Jeffrey 7
∞
Robert S. and Raissa H. Johnson 9
Richard Jonas and Katherine Vernot-Jonas 10
∞
Michael M. Kaback, M.D. 2
∞
Gurdyal Kalsi, M.D.
Charles E. Kaufman Medical Fund 5
∞
Ronald L. Krall, M.D. and Susan J. Krall 11
Kumar Family Charitable Fund 2
∞
Ann Lemmon 2
∞
Ron Levenbaum, D.M.D. 2
Ahmed Mahmoud 2
∞
Marathon Asset Management
Robert F. Marino 7
In memory of Frank and Juanita Marino
Cathleen Martin 5
∞
The Honorable Matthew McHugh 2
∞
Donna Mckelvey
Ari and Abbey Meltzer 3
∞
Allen Morris and Barbara Bissell 6
∞
Stephen F. Murphy 2
∞
Gretchen Naylor Netflix 5
∞
Kenneth W. Odom
Gretchen Naylor
∞
Gilbert S. Omenn, M.D., Ph.D. and Martha A. Darling 10
∞
Steven and Kimberlee Owens 2
∞
In memory of Laurie Kemna & L. D. Reynolds
Farhan Panthaki 2
∞
Marilyn H. Paul 2
∞
Robert and Paula Petterson 5
∞
Anne Pfaelzer De Ortiz 2
∞
Eric F. Polhaumus 2
∞
The Relias Family 1
∞
John S. Rhim, M.D. 5
Lorene Steinberg
In memory of Steven Steinberg
∞
Christopher and Elizabeth Thoma 1
∞
William, Zani and Aycen Tolentino 9
∞
Claire E. Toth
In honor of Carol-Ann Harris
Anne S. Tsukuda 9
∞
Eugene J. Van Scott, M.D. 2
∞
Paula J. Warrick, Ph.D. 5
∞
Robert C. Watson and Debra D. Petersen 7
∞
West American Rubber Company, LLC
In memory of Harold L. Slucher
Julie and Howard Wolf-Rodda 11
∞
Steven Wong 1
∞
Brett Wood
∞
Dr. Stuart H. Yuspa and Eleanor H. Yuspa 5
Anonymous (4)
Amazon Smile Foundation
American Express Company
Jeffrey and Ann Anderson
Diego Ardila
In honor of Laura Ardila
Miriam Arocho
Stephen D. and Margie C. Ban
In honor of Sophia Trujillo
Jill H. Barr
In memory of John L. Barr
Ann Beck
Joan Beck
Stuart J. and Ruth Brahs
Dana Bresin
In honor of Laura C. Hazzard
Ryan Brown
In memory of Brian Griffin
Martin J. Corso, M.D.
Mary Frances Cotch and B. Fenton Hall
Daniel Czamecki
Rosemary Dawicki
Larry Day
Jeffrey J. Doenges
Marguerite Durkin
Jeffrey Dwoskin
Faye Fager
Arlene L. Feit
Michelle M. Frack
David A. Fryburg, M.D.
Daniel T. and Amy Moor Gallmeyer
Gartner, Inc.
Jason and Gloria Garver
Thomas Gasparini
Margaret Gavin
Dr. Martin Gellert
Peggy J. Gerlacher
In memory of John D. Gerlacher
Michael Gottlieb, Ph.D. and Joan Gottlieb
In honor of the Staff of the Foundation for the National Institutes of Health
Sam D. Graham, M.D. and Jane O. Graham
Gerald Haley
Eric J. and Susan Hatch
Chris Hauck
In memory of Mary L. Rhim
Robert Heady
Henry L. Hecht
In honor of Stuart H. Yuspa
D. Henderson
Greg and Sally Henderson
In honor of Christene Kazanas
Eva C. Holtz
James Horton, M.D.
Howard County General Hospital
In memory of Brian Griffin
Kathleen M. Hunn
Intel Corporation
George Isaac
Raymond James
Youngmi Ji, Ph.D.
In memory of Mary L. Rhim
Norris Johnson
In memory of Timothy J. Johnson
Chien Yuan Kao
Samanta Kaplan
Anne Kelly
John A. Kennedy
Amanda Kirk
Paul and Nancy Kurland
Brian Ladd
Thomas A. and Nancy L. Lusk
Greg Lytle
In memory of Mary L. Rhim
Dr. Adel A. Mahmoud and Dr. Sally Hodder
Anne Alexander
Marshall, Ph.D. and Davis Marshall
Travis McCaw
Microsoft Corporation
Stephen A. Migueles
Gloria Monarrez
Jorge Morazzani
Jonathan Moskow
Susan M. Nebinski
In memory of Stan C. Nebinski
Benjamin S. and Elizabeth F. Neufeld, Ph.D.
Byong Park
Nora Phillips
Christopher Pike
In memory of Thomas Pike
Timothy Ponden
William J. Price
Jacqueline Ratner
Arnold C. Rausch and Renee Puzio
Robert Rea
Sangam V. Reddy
Michael J. Richman
James and Lora Rodenberg
In memory of Dennis Rodenberg
Judy Rose
In memory of Mary L. Rhim
Sidney Rosenzweig
Walter G. Rostykus and Catherine Elliott-Rostykus
Michael Roytburd
Janice W. Rutherford
Dr. Michael Ryan and Dr. Linda Ryan
Darren Schneider
Mary Jo Shapiro
Richard and Elizabeth Slucher
In memory of Harold L. Slucher
Rainer F. Storb, M.D.
Anthony Tassone
Harold E. Varmus, M.D.
David Vigil
Matthew Warnecke
Theodore Wells
Wiley Rein LLP
Ingrid Wiley
Xcel Energy Inc.
Joyce A. Yarington
In memory of Lila Wilson
Joel Yesley
### Revenue and Support

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$58,518,484</td>
<td>$80,605,604</td>
</tr>
<tr>
<td>Grants</td>
<td>381,969</td>
<td>351,613</td>
</tr>
<tr>
<td>Administrative fee</td>
<td>111,660</td>
<td>122,392</td>
</tr>
<tr>
<td>Government appropriations</td>
<td>1,110,000</td>
<td>1,150,000</td>
</tr>
<tr>
<td>Investment earnings</td>
<td>2,443,260</td>
<td>1,102,491</td>
</tr>
<tr>
<td>In-kind contributions</td>
<td>1,490,818</td>
<td>960,688</td>
</tr>
<tr>
<td>Donated services</td>
<td>39,000</td>
<td>30,000</td>
</tr>
<tr>
<td>Fundraising event</td>
<td>324,700</td>
<td>279,800</td>
</tr>
<tr>
<td><strong>Total revenue and support</strong></td>
<td><strong>$64,419,891</strong></td>
<td><strong>$84,602,588</strong></td>
</tr>
</tbody>
</table>

### Expenses and changes in net assets

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Program services</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fellowships and training programs</td>
<td>$958,145</td>
<td>$1,257,933</td>
</tr>
<tr>
<td>Memorials, awards and events</td>
<td>813,509</td>
<td>390,128</td>
</tr>
<tr>
<td>Capital projects</td>
<td>66,782</td>
<td>51,627</td>
</tr>
<tr>
<td>Research programs</td>
<td>49,897,652</td>
<td>41,957,442</td>
</tr>
<tr>
<td><strong>Total program services</strong></td>
<td><strong>$51,736,088</strong></td>
<td><strong>$43,657,130</strong></td>
</tr>
<tr>
<td><strong>Supporting services</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management and general</td>
<td>$4,986,112</td>
<td>$3,800,393</td>
</tr>
<tr>
<td>Fundraising</td>
<td>438,402</td>
<td>392,283</td>
</tr>
<tr>
<td><strong>Total supporting services</strong></td>
<td><strong>$5,424,514</strong></td>
<td><strong>$4,192,676</strong></td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>$57,160,602</strong></td>
<td><strong>$47,849,806</strong></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$7,259,289</td>
<td>$36,752,782</td>
</tr>
<tr>
<td>Net assets beginning of year</td>
<td>103,228,330</td>
<td>66,475,548</td>
</tr>
<tr>
<td><strong>Net assets at end of year</strong></td>
<td><strong>$110,487,619</strong></td>
<td><strong>$103,228,330</strong></td>
</tr>
</tbody>
</table>
Board of Directors
As of December 2017

Officers

Steven M. Paul, M.D.
CHAIRMAN

Maria C. Freire, Ph.D.
PRESIDENT AND EXECUTIVE DIRECTOR

Solomon H. Snyder, M.D.
VICE CHAIRMAN

Steven C. Mayer
TREASURER

Mrs. William McCormick Blair, Jr.
SECRETARY

Elected Directors

Kathy Bloomgarden, Ph.D.
Buffy Cafritz
James H. Donovan
Paul L. Herrling, Ph.D.
Thomas R. Insel, M.D.
Judy Lansing Kovler, Ph.D.
Ronald L. Krall, M.D.
Freda C. Lewis-Hall, M.D., DFAPA
Edison T. Liu, M.D., Ph.D.
Joel S. Marcus
Paul M. Montrone, Ph.D.
Martin J. Murphy Jr., Ph.D., DMedSc, FASCO
Jillian Sackler, D.B.E.
Lily Safra
Charles A. Sanders, M.D.
Fred Seigel
Ellen V. Sigal, Ph.D.
Nina K. Solarz
Russell W. Steenberg
Paul Stoffels, M.D.
Samuel O. Thier, M.D.

Ex Officio

Francis S. Collins, M.D., Ph.D.
Scott Gottlieb, M.D.

Directors Emeritus

Paul Berg, Ph.D.
Sherry Lansing
The Honorable
John Edward Porter

Honorary Directors

Luther W. Brady, M.D.
Ann Lurie
Patrick C. Walsh, M.D.